In early December 2019, cases of pneumonia of unknown origin were reported in Wuhan,Hubei Province in the People's Republic of China. The disease spreads rapidly and thenumber of sick people is increasing. On January 3, 2020 a new virus of the coronavirusfamily is identified in samples of bronchoalveolar lavage fluid from a patient in Wuhanand subsequently confirmed as the cause of these pneumonias. On 7 January 2020, the WorldHealth Organization (WHO) designated it as the new coronavirus 2019 (i.e. 2019-nCoV). On11 February 2020, the WHO designated the disease associated with 2019-nCoV as coronavirus2019 disease (COVID-19). On 12 March, WHO announced that the COVID-19 outbreak is apandemic.As of March 24, 2020, more than 375,000 cases of COVID-19 had been diagnosed with morethan 16,000 deaths attributed to this virus. (Ref WHOhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019 ).In France, the number of cases rose from 105 cases at the end of February to 19615confirmed cases on March 24. (Source Public Health France). Most of the cases are adults.However, children are not completely spared and serious cases have been described. Thesesevere cases can be respiratory or extra-respiratory (e.g. myocarditis). We also knowthat pediatric and adult cases differ in terms of clinical, biological and imagingfindings, particularly chest CT scans. However, the description of paediatric pictures,especially severe forms and the involvement of children suffering from co-morbidities,remains poorly reported. Finally, the risk factors for serious cases in children remainlargely unknown.This observatory aim to describe the clinical phenotypes of hospitalized pediatricpatients with Covid19 in France, according to age groups. Moreover for a subgroup ofpatients, informations regarding the long covid will be reported.

Our long-term goal is to protect the health care workforce (HCW) caring forSARS-CoV-2-infected patients, their families, communities, and the general population.Our specific objective is to rapidly establish a prospective cohort to characterize thefactors related to viral transmission and disease severity in a large healthcare system.We addressed this hypothesis by recruiting and longitudinally following 546 HCW and acomparison group of 283 non-HCW within a large academic health system, Rutgers Biomedicaland Health Sciences (RBHS). By intensively following participants over a several yearperiod (2020-2024) and collecting serial biospecimens (nasopharyngeal/throat swabs,blood, and saliva) and questionnaire data at multiple time points, we will uniquelycharacterize SARS-CoV-2 transmission and risk factors for COVID-19 among HCW and ourlarger academic community.

Since December 2019, the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)pandemic has spread around the world. The people most exposed to this virus remain thehealthcare personnel who are on the front line in the fight against this pandemic. Due tothe delayed nature of the pandemic in Reunion island and its insular geographicalsituation, the study of the voluntary medical personnel will allow the investigators toestablish a longitudinal follow-up of the anomalies of the lipidic balance in relation tothe exposure to the SARS-Cov virus. 2. During bacterial infections, the lipid profilesare profoundly modified with very significant reductions in plasma cholesterol levels,LDL-C but especially HDL-C whose concentrations are particularly low. Lipid profiles arealtered during viral infections, for example, the severity of dengue is inverselycorrelated with total cholesterol and LDL-C but not with HDL-C levels, according to arecent meta-analysis. The hepatitis C virus circulates in serum linked to lipoproteinsrich in triglycerides and HDL can facilitate its entry into cells via Scavenger receptorclass B type 1 (SRB1). Likewise, it has been shown that apoA1 can bind to the denguevirus and increase its infectivity by promoting its entry into cells, also via SRB1. Atthe moment, nothing is known about the lipid profiles in subjects with SARS-CoV-2. Theinvestigator hypothesize that a drop in plasma HDL-C levels and a change in their sizeduring infection could justify future therapeutic approaches aimed at supplementing thesubjects most at risk of pulmonary complications. In a model of Pseudomonas aeruginosapneumonia in mice, investigators have shown that the injection of reconstituted HDLallowed to limit the pulmonary inflammation and the deleterious consequences of theinfection. The investigator propose to study not only the lipid profiles in subjects whoare infected with SARS-CoV-2 but also the polymorphisms of genes involved in theregulation of lipoprotein levels like that of Cholesterol Ester-Transfer Protein (CETP)depending on the developed forms, symptomatic or not.

DESIGN Longitudinal prospective observational multicentre study.Primary objective:Understand the immune mechanisms driving COVID-19 disease in patients with a history oflung disease

This is a prospective cohort observational registry study that will include data on allpatients who are treated at MHS facilities for COVID-19.

The aim of this work is to conduct a randomized, double-blind, placebo-controlledclinical trial to assess the efficacy and safety of cannabidiol (CBD - 300 mg a day) inpatients infected with SARS-CoV-2.The specific objectives are to assess whether, in patients with mild and moderate formsof SARS-CoV-2, daily use of CBD 300 mg for fourteen days is capable of:i) decrease viral load; ii) modify inflammatory parameters, such as cytokines, measuredfrom serum; iii) reduce clinical and emotional symptoms through daily clinicalevaluation; iv) improve sleep; v) reduce hospitalization and worsen the severity of thedisease; v) Monitor the possible adverse effects of CBD use in these patients.

: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acuterespiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developedSAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc]bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluatethe safety, immunogenicity, and pharmacokinetics of SAB-185 in ambulatory participantswith COVID-19.

COVID-19 is a community acquired pneumonia caused by infection with a novel coronavirus,SARS CoV2 and is a serious condition with high mortality in hospitalised patients, forwhich there is no currently approved treatment other than supportive care. Urgentinvestigation of potential treatments for this condition is required.This protocol describes an overarching and adaptive trial designed to provide safety,pharmacokinetic (PK)/ pharmacodynamic (PD) information and exploratory biologicalsurrogates of efficacy which may support further development and deployment of candidatetherapies in larger scale trials of COVID-19 positive patients receiving normal standardof care.Given the spectrum of clinical disease, community based infected patients or hospitalisedpatients can be included. Products requiring parenteral administration will only beinvestigated in hospitalised patients. Patients will be divided into cohorts, a)community b) hospitalised patients with new changes on a chest x-ray (CXR) or a computedtomography (CT) scan or requiring supplemental oxygen and c) hospitalised requiringassisted ventilation. Participants may be recruited from all three of these cohorts,depending on the experimental therapy, its route of administration and mechanism ofaction. The relevant cohort(s) for any given therapy will be detailed in thetherapy-specific appendix.Candidate therapies can be added to the protocol and previous candidates removed fromfurther investigation as evidence emerges. The trial will be monitored by an independentData Monitoring Committee (DMC) to ensure patient safety.Each candidate cohort will include a small cohort of patients randomised to candidatetherapy or existing standard of care management dependent on disease stage at entry.Cohort numbers will be defined in the protocol appendices.This is a Phase IIa experimental medicine trial and as such formal sample sizecalculations are not appropriate.

The primary purpose of this study is to gain an understanding of how experiences duringthe COVID-19 pandemic, regardless of COVID-19 status, may have impacted multiple domainsof health-related quality of life and other areas such as COVID-19 specific psychologicaldistress, and disruptions to health care, finances and social interactions. We will alsoevaluate the extent to which resiliency factors such as social support, perceivedbenefits under times of stress, and ability to manage stress may buffer associationsbetween COVID-19 experiences and HRQoL. To meet these objectives, we have developed a10-minute questionnaire that taps into these areas and is based on prior work addressingconcerns of other pandemics or national crises. Participants will have previouslyconsented to protocol PA15-0336 and have provided prior lifestyle data. This will allowus to connect the COVID-19 survey data with prior existing data.

This is a prospective, randomized, single-center, open-label controlled trial, designedto compare the efficacy of two ventilation strategies (Low Tidal Volume and positiveend-expiratory pressure (PEEP) based on the Acute Respiratory Distress Syndrome (ARDS)Network low PEEP-fraction of inspired oxygen inspired oxygen fraction (FIO2) Table versusLow Driving Pressure and PEEP guided by Electrical Impedance Tomography (EIT) in reducingdaily lung injury score in patients with acute respiratory distress syndrome caused byCOVID-19. The two strategies incorporate different prioritizations of clinical variables.The PEEP-FIO2 table strategy aims to reduce lung overdistension, even if it requirestolerating worse gas exchange. EIT-guided strategy prioritizes mechanical stressprotection, avoiding alveolar overdistension and collapse.